Group items tagged

Recently, a variety of biopharmaceuticals have come to be used in clinical practice. Macromoleculardrugs, however, are extremely difficult to absorb from the gastrointestinal tract; also, they are mainly administered through injection, which is associated with pain upon administration and would pose a great burden on patients. From the viewpoint of stability of medicinal products, many medicines should be refrigerated, resulting in reduced work or production efficiency in clinical or manufacturing practice, respectively.

1) Liver Scholar Awards: Three-year grants of up to $225,000 will be awarded in support of basic science research projects. The goal of the program is to provide young scientists with support at an early stage of their careers to bridge the gap between completion of their research training and attainment of status as an independent research scientist. While applications on all liver-related research topics will be considered, preference will be given to projects related to biliary atresia and primary biliary cirrhosis. 2) Postdoctoral Research Fellowship Award: One-year grants of up to $12,500 will be awarded to support MD, PhD, and MD/PhD postdoctoral fellows in their first or second year of appointment as a postdoctoral research fellow or trainee and who seek professional development, additional training, and experience in liver research. The foundation encourages projects related to transplantation, autoimmune hepatitis, hepatitis, primary sclerosing cholangitis, biliary atresia, and primary biliary cirrhosis. 3) Primary Biliary Cholangitis (PBC) Fund for the Cure Award: The PBC Fund for the Cure Award is a one-year award of $100,000 that provides support for a faculty member to initiate a project that addresses a novel and important research question related to the process by which primary biliary cholangitis attacks the liver. The proposed investigation may involve basic, clinical, or translational research. The award supports investigational work related but not limited to pathophysiological studies, clinical trials and applications, or assessment of new diagnostic and/or therapeutic modalities.

The 2017 Building Trust and Mutual Respect to Improve Health Care call for proposals (CFP) will fund empirical research studies to help us better understand how to build trust and mutual respect to meet vulnerable patients' health care needs. For this CFP, we would define vulnerable populations in a number of different ways, including the economically disadvantaged, diverse racial and ethnic populations, the uninsured, older adults, homeless individuals, and people with complex health and social needs (including people with acute behavioral health needs or multiple chronic conditions). Proposals most closely aligned with the scope of this CFP will go beyond documenting the problem to generate findings that will be generalizable and have broad application across health systems and the field. Eligibility and Selection Criteria · Researchers, as well as practitioners in the public and private sector working with researchers, are eligible to submit proposals through their organizations. Projects may be generated from disciplines including health services research; economics; sociology; program evaluation; political science; public policy; psychology; public health; public administration; law; business administration; or other related fields. · The Foundation may give preference to applicants that are either public entities or nonprofit organizations that are tax-exempt under Section 501(c)(3) of the Internal Revenue Code and are not private foundations or Type III supporting organizations. · The Foundation may require additional documentation. Applicant organizations must be based in the United States or its territories.

The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Tissue Mapping Centers (TMCs) that will generate high-resolution, high-content, multiscale maps of non-diseased human organs and systems. Centers will be expected to integrate and optimize all parts of the data generation pipeline, from tissue collection and preservation through to data integration, analysis and interpretation. Centers will also be expected to work closely with the other funded projects as part of the Human BioMolecular Atlas Program to catalyze development of a framework for mapping the human body at high resolution.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit transformative technologies that will significantly expand throughput, multiplexing and discrimination of biomolecules in human tissues for comprehensive mapping of individual cells and their context in human tissues. This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and systems that can be integrated, scaled and applied to multiple human tissues. The initial two-year UG3 phase will support accelerated development and demonstration of feasibility of these emerging, high impact technologies. The subsequent two-year UH3 phase will support validation in human tissues, optimization, scale-up, and generation of data. Funded projects will be expected to work closely as part of the Human BioMolecular Atlas Program to catalyze development of a framework for mapping the human body with high resolution.

This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

The MPS DC is expected to be the central clearinghouse for TC data management, and will incorporate novel approaches and technologies for data management, data mining and meta-analyses, and data sharing across many organs and tissues, diseases, data types, and TC platforms. The MPS Data center is expected to provide different levels of public and tiered access to TC information for basic and clinical researchers, academic and practicing physicians, the pharmaceutical industry, NIH, FDA and other government agencies, patients, and the lay public. The MPS Data Center will work with IQ Consortium members to develop and make available a secure, customizable coordinated data management system for collection, storage, and analyses of diverse data types from multiple TC platforms being developed and used for drug screening, safety and efficacy testing.

The McKnight Endowment Fund for Neuroscience supports innovative research designed to bring science closer to the day when diseases of the brain can be accurately diagnosed, prevented, and treated. To that end, the McKnight Endowment Fund for Neuroscience invites Letters of Intent for its 2018 McKnight Technological Innovations in Neuroscience awards. The program encourages and supports scientists working on the development of novel and creative approaches to the understanding of brain function. McKnight is interested in how a new technology may be used to monitor, manipulate, analyze, or model brain function at any level, from the molecular to the entire organism. Technology may take any form, from biochemical tools to instruments to software and mathematical approaches. Because the program seeks to advance and enlarge the range of technologies available to the neurosciences, research based primarily on existing techniques will not be considered. A goal of the Technological Innovations awards is to foster collaboration between the neurosciences and other disciplines; therefore, collaborative and cross-disciplinary applications are explicitly invited.

The purpose of this FOA is to stimulate much needed research in an important area of public health significance: prevention of new HIV infections among adolescents at risk, and the identification of, linkage to and retention in care of, and long term viral suppression among youth living with HIV in low-to-middle income countries. These settings must have an HIV epidemic density defined by UNAIDS estimates as either a country 1) in which at least 200,000 people are living with HIV and the number has not decreased by more than 5% over the last 2 consecutive years of available data or 2) has an HIV prevalence of 3% or more. The UG3/UH3 Phased Innovation Awards Cooperative Agreement involves 2 phases. Funding for a UG3 phase will be used to demonstrate sufficient preparation, feasibility and capacity to meet foundational milestone targets specific to the work proposed. A UG3 project that meets its milestones will be administratively considered by NICHD and prioritized for transition to the UH3 award. Applicants responding to this FOA must address objectives for both the UG3 and UH3 phases.

NSF INCLUDES (Inclusion across the Nation of Communities of Learners of Underrepresented Discoverers in Engineering and Science) is a comprehensive national initiative designed to enhance U.S. leadership in science, technology, engineering, and mathematics (STEM) discoveries and innovations by focusing on broadening participation in these fields at scale. The vision of NSF INCLUDES is to catalyze the STEM enterprise to collaboratively work for inclusive change, which will result in a STEM workforce that reflects the population of the Nation. The initiative is developing a National Network composed of NSF INCLUDES Design and Development Launch Pilots, NSF INCLUDES Alliances, an NSF INCLUDES Coordination Hub, NSF-funded broadening participation projects, other relevant NSF-funded projects, scholars engaged in broadening participation research, and other organizations that support the development of talent from all sectors of society to build an inclusive STEM workforce.

Supported by the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH), EMF is inviting applications for its EMF/NIDA Mentor-Facilitated Training Award in Substance Use Disorders Science Dissemination. The award seeks works that addresses the overarching goals of EMF, including the promotion of knowledge of evidence-based SUD treatment among healthcare providers; the dissemination of substance use disorder research finding; the adoption of evidence-based approaches in medical settings, and the facilitation of the academic growth and development of future leaders in SUD management.

This Funding Opportunity Announcement (FOA) solicits renewal applications for Biobanks that will support the following NCI clinical trial programs: The NCI National Clinical Trials Network (NCTN; https://research.usc.edu/nci-national-clinical-trials-network-nctn-program/), and NCI Community Oncology Research Program (NCORP). The NCTN Biospecimen Bank (also referred to as NCTN Biobanks) will be responsible for collecting, processing, storing, and distributing well-annotated human specimens from patients with cancer who are participating in NCI-funded NCTN Phase II-III and other clinical treatment trials (CTEP/Division of Cancer Treatment and Diagnosis; DCTD). The main goal is to support NCTN with the state-of the-art banking infrastructure and operations including maintenance of up-to-date specimen inventory. The NCTN Biobanks will distribute to qualified investigators the biospecimens linked to high-quality clinical data (including treatment and outcome information) that are critical for developing and validating biomarkers for cancer diagnosis, prognosis and prediction of responses to therapy. The NCTN Biobanks will work in collaboration with NCTN Groups and Group Statistical and Data Management Centers as well as affiliated institutions to ensure effective operation. Each Biobank needs to maintain association with one specific NCTN Group and needs to be endorsed in that role by the group leaders. NCTN Biobanks will also support biobanking and storage of biospecimens from NCORP cancer control and prevention trials (NCORP/Division of Cancer Prevention; DCP).

The Understanding the Rules of Life: Microbiome Theory and Mechanisms (URoL:MTM) program is an integrative collaborationacross Directorates and Offices within the National Science Foundation. The objective of URoL:MTM is to understand and establish the theory and mechanisms that govern the structure and function of microbiomes, a collection of microbes in a specific habitat/environment. This may include but is not limited to host-associated microbiomes, such as those with humans and other organisms, where i) the microbiome impacts host physiology, behavior, development, and fitness; ii) the host influences the metabolic activity, dynamics and evolution of the microbiome, and iii) the environment (biological, chemical, physical, and social) influences and is influenced by both the host and the microbiome. Recent progress has transformed our ability to identify and catalogue the microbes present in a given environment and measure multiple aspects ofbiological, chemical, physical, and social environments that affect the interactions among the members of the microbiome, the host, and/or habitat. Much descriptive and correlative work has been performed on many microbiome systems, particularly those in the human, soil, aquatic, and built environments. This research has resulted in new hypotheses about the microbiome's contributions to potential system function or dysfunction. The current challenge is to integrate the wide range of accumulated data and information and build on them to develop new causal/mechanistic models or theories of interactions and interdependencies across scales and systems.

The DOE SC program in Biological and Environmental Research (BER) hereby announces its interest in receiving applications for research in Environmental Systems Science (ESS), including Terrestrial Ecosystem Science (TES) and Subsurface Biogeochemical Research (SBR). The goal of the Environmental System Science (ESS) activity in BER is to advance a robust, predictive understanding of the set of interdependent physical, biogeochemical, ecological, hydrological, and geomorphological processes for use in Earth system, ecosystem and reactive transport models. Using an iterative approach to model-driven experimentation and observation, and interdisciplinary teams, ESS-supported scientists work to unravel the coupled physical, chemical and biological processes that control the structure and functioning of terrestrial ecosystems and integrated watersheds across critical spatial and temporal scales. This FOA will consider applications that focus on improving the understanding and representation of terrestrial and subsurface environments in ways that advance the sophistication and capabilities of local, regional, and larger scale models.

The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Tissue Mapping Centers (TMCs) that will generate high-resolution, high-content, multiscale maps of non-diseased human organs and systems. Centers will be expected to integrate and optimize all parts of the data generation pipeline, from tissue collection and preservation through to data integration, analysis and interpretation. Centers will also be expected to work closely with the other funded projects as part of the Human BioMolecular Atlas Program to catalyze development of a framework for mapping the human body at high resolution.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit transformative technologies that will significantly expand throughput, multiplexing and discrimination of biomolecules in human tissues for comprehensive mapping of individual cells and their context in human tissues. This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and systems that can be integrated, scaled and applied to multiple human tissues. The initial two-year UG3 phase will support accelerated development and demonstration of feasibility of these emerging, high impact technologies. The subsequent two-year UH3 phase will support validation in human tissues, optimization, scale-up, and generation of data. Funded projects will be expected to work closely as part of the Human BioMolecular Atlas Program to catalyze development of a framework for mapping the human body with high resolution.

The purpose of this award is to support phased transition of outstanding graduate students from groups underrepresented in the biomedical, clinical, behavioral and social sciences research enterprise from graduate work to postdoctoral research positions in Dental, Oral, and Craniofacial (DOC) research. The first phase (F99) will support the final two years of graduate research training for individuals in PhD or dual degree clinician scientist programs. Following graduation and attainment of a postdoctoral research position, the second phase (K00) will provide support for up to three years of mentored postdoctoral research.

The intent of the FY19 PRARP CSRA is to support innovative or novel efforts to generate research resources, tools, or research efforts for researchers and/or practitioners in health sciences related to the PRARP's mission (see Section II.A, Program Description). The proposed work should innovatively challenge existing research paradigms or exhibit high levels of creativity within the contexts of the PRARP's mission and vision. The research innovations for the FY19 PRARP CSRA are expected to benefit the military, Veteran, and civilian communities. FY19 PRARP CSRA applications should be Innovation- and Impact-based.

The purpose of this Funding Opportunity Announcement (FOA) is to build upon the work that has begun under previous FOA RFA-TR-17-007 "NCATS Pilot Program for Collaborative Drug Discovery Research Using Bioprinted Skin Tissue" and utilize physiologically relevant and validated 3-D biofabricated skin disease tissue models in multi-well drug screening platforms. The FOA will support intramural- extramural collaborations to implement the use of 3-D biofabricated skin tissue models and provide evidence of success for 3-D drug screening platforms.

The purpose of this Funding Opportunity Announcement (FOA) is to build upon the work that has begun under previous FOA RFA-TR-17-007 NCATS Pilot Program for Collaborative Drug Discovery Research Using Bioprinted Skin Tissue and utilize physiologically relevant and validated 3-D biofabricated skin disease tissue models in multi-well drug screening platforms. The FOA will support intramural- extramural collaborations to implement the use of 3-D biofabricated skin tissue models and provide evidence of success for 3-D drug screening platforms.